What changed: Rosai-Dorfman-Destombes disease
Every dated change on the records linked to Rosai-Dorfman-Destombes disease, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2022 · 1
2018 · 6
- 2018GuidelineRosai-Dorfman-Destombes diseaseGuideline Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018): Asymptomatic nodal or cutaneous disease
Observation, because spontaneous regression is common.
- 2018GuidelineRosai-Dorfman-Destombes diseaseGuideline Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018): Diagnosis and staging
Excisional biopsy with immunohistochemistry and MAPK pathway sequencing; FDG-PET/CT; MRI where neurological disease is suspected; immunoglobulins and autoimmune screen.
- 2018GuidelineRosai-Dorfman-Destombes diseaseGuideline Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018): MAPK-mutant or refractory disease
Cobimetinib (approved 2022 for histiocytic neoplasms) or trametinib.
- 2018GuidelineRosai-Dorfman-Destombes diseaseGuideline Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018): Multifocal or organ-threatening disease
Corticosteroids for rapid control; sirolimus with prednisone, cladribine, methotrexate or lenalidomide; rituximab for IgG4-associated disease.
- 2018GuidelineRosai-Dorfman-Destombes diseaseGuideline Consensus recommendations for Rosai-Dorfman-Destombes disease (Blood 2018): Single or compressive extranodal lesion
Surgical excision or debulking; radiotherapy for unresectable localised disease (orbit, airway).
- 2018MilestoneRosai-Dorfman-Destombes diseaseFirst consensus recommendations for diagnosis and treatment (Blood)
A milestone in how this cancer is treated.